Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrophogenic Potential of Eflornithine in Women With Excessive Facial Hair
NCT00152048Phase 4Completed
- Sponsor
- Allergan
- Start
- Nov 2004
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in hirsutism comparing Eflornithine with Placebo (2 arms). Primary endpoint: Change in facial skin thickness measured by ultrasound at 24 weeks. Started Nov 2004; status: completed.
02
Drugs
eflornithine
03
Conditions
hirsutism
Beyond the preview
Go deeper on NCT00152048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152048.